TLDR
- Quantinuum’s IPO and new listings show quantum computing moving toward real commercial use.
- Amgen and Cleveland Clinic are testing quantum systems for drug discovery and research.
- The U.S. Commerce Department pledged $2 billion in May to speed up quantum development.
- IonQ reported record quarterly revenue of $80.1 million, up 287% year over year.
- Bank of America started coverage of IonQ with a Buy rating and a $60 price target.
Quantum computing has emerged as a focal point for Wall Street investors throughout this year. The sector has witnessed multiple companies entering public markets, with Quantinuum’s recent listing representing a notable transition from pure academic exploration to practical business deployment.
Major technology corporations are expanding their quantum initiatives. Microsoft launched a dedicated quantum research facility in Maryland last month. IonQ announced that its latest computing system will be installed at Nvidia’s quantum research facility.
A research publication recently highlighted how IBM’s Nighthawk processor completed a computational challenge in just 19 secondsāa task that conventional supercomputers would require 110 years to solve.
International Business Machines Corporation, IBM
Healthcare Companies Testing Quantum Systems
Pharmaceutical organizations represent some of the earliest adopters exploring quantum computing for practical applications. Amgen, a global pharmaceutical leader, is leveraging the technology in efforts to accelerate drug development timelines.
Amgen participated as a primary investor in Quantinuum’s initial significant financing round. The pharmaceutical giant also maintains a working relationship with quantum computing company QuEra.
Cleveland Clinic has maintained an active quantum computing initiative for half a decade. What began as a modest pilot has evolved into an extensive collaboration with IBM encompassing over 60 initiatives across artificial intelligence, advanced computing, and quantum exploration.
Scientists from Cleveland Clinic, IBM, and Japan’s Riken research institute received a nomination for the ACM Gordon Bell prize recognizing their breakthrough work in protein modeling. Cleveland Clinic’s chief research information officer noted that the nomination provided important credibility for quantum research as a worthwhile institutional investment.
Government Funding And Security Concerns
Federal authorities are channeling significant resources into quantum research initiatives. The Commerce Department unveiled a $2 billion funding commitment in May designed to accelerate technological advancement and establish a functional system at a national laboratory facility by 2028.
Some of this urgency stems from cybersecurity considerations. An algorithm known as Shor’s algorithm theoretically possesses the capability to compromise existing encryption standards, although it hasn’t been successfully deployed for that purpose to date.
Cloud infrastructure providers including Amazon Web Services and Microsoft currently offer developers quantum computing access without requiring physical hardware ownership. This accessibility could potentially accelerate both beneficial applications and security risks, according to Booz Allen’s quantum technology leader.
Within publicly traded companies, IonQ has captured sustained analyst interest. Bank of America initiated coverage on the stock with a Buy recommendation and a $60 price objective, highlighting the company’s trapped ion approach and its acquisition of semiconductor manufacturer SkyWater Technology.
IonQ disclosed second quarter revenue reaching $80.1 million, representing a 287% increase compared to the prior year period. However, the company’s net loss per share expanded to $5.08 from $0.70 during the equivalent quarter last year.
IonQ has unveiled additional strategic partnerships this fall. The company secured an agreement to deliver a quantum computer to South Korea’s SDT and announced it will execute the first on-premise quantum installation at Nvidia’s research facility.
Additional participants in the sector include Rigetti Computing, D-Wave Quantum, and Xanadu Quantum Technologies. Xanadu entered public markets in March via a merger with a special purpose acquisition company and has experienced a stock decline exceeding 39% during the past six months.
Xanadu disclosed second quarter revenue of $1.5 million, declining from $2.8 million in the first quarter. The company maintained $312.8 million in cash and liquid assets as of June 30.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
